[1. Hanahan, D. and R.A. Weinberg: The Hallmarks of Cancer; Cell 100 (2000) 57-70.]Search in Google Scholar
[2. Vogelstein, B., N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz, Jr, and K.W. Kinzler: Cancer Genome Landscapes; Science 339 (2013) 1546-1558.]Search in Google Scholar
[3. Raparia, K., C. Villa, M.M. DeCamp, J.D. Patel, and M.P. Mehta: Molecular Profiling in Non-Small Cell Lung Cancer: A Step Toward Personalized Medicine; Arch. Pathol. Lab. Med. 137 (2013) 481-491.]Search in Google Scholar
[4. Rosai, J.: Rosai and Ackerman’s Surgical Pathology, 9th ed., Mosby, Edinburgh, UK, 2004.]Search in Google Scholar
[5. Coolidge v. Philip Morris Inc., RIC361063 Superior Court of California, Riverside County, Dept. 6 (2005).]Search in Google Scholar
[6. Khuder, S.A.: Effect of Cigarette Smoking on Major Histological Types of Lung Cancer: A Meta-Analysis; Lung Cancer 31 (2001) 139-148.]Search in Google Scholar
[7. Rudin, C.M., E. Avila-Tang, C.C. Harris, J.G. Herman, F.R. Hirsch, W. Pao, A.G. Schwartz, K.H. Vahakangas, and J.M. Samet: Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications; Clin.Cancer Res. 15 (2009) 5646-5661.]Search in Google Scholar
[8. Pesch, B., B. Kendzia, P. Gustavsson, K.-H. Jöckel, G.Johnen, H. Pohlabeln, A. Olsson, W. Ahrens, I.M.Gross, I. Brüske, H.-E. Wichmann, F. Merletti, L.Richiardi, L. Simonato, C. Fortes, J. Siemiatycki, M.-E.Parent, D. Consonni, M.T. Landi, N. Caporaso, D.Zaridze, A. Cassidy, N. Szeszenia-Dabrowska, P. Rudnai, J. Lissowska, I. Stücker, E. Fabianova, R.S.Dumitru, V. Bencko, L. Foretova, V. Janout, C.M.Rudin, P. Brennan, P. Boffetta, K. Straif, and T.Brüning: Cigarette Smoking and Lung Cancer- Relative Risk Estimates for the Major Histological Types from a Pooled Analysis of Case-Control Studies; Int. J. Cancer 131 (2012) 1210-1219.]Search in Google Scholar
[9. Devesa, S.S., F. Bray, A.P. Vizcaino, and D.M. Parkin: International Lung Cancer Trends by Histologic Type: Male:Female Differences Diminishing and Adeno- carcinoma Rates Rising; Int. J. Cancer 117 (2005) 294-299.]Search in Google Scholar
[10. Doll, R., A.B. Hill, and L. Kreyberg: The Significance of Cell Type in Relation to the Aetiology of Lung Cancer; Br. J. Cancer 11 (1957) 43-48.]Search in Google Scholar
[11. Travis, W.D., E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, Y. Yatabe, D.G. Beer, C.A. Powell, G.J. Riely, P.E. Van Schil, K. Garg, J.H.M Austin, H. Asamura, V.W. Rusch, F.R. Hirsch, G. Scagliotti, T. Mitsudomi, R.M. Huber, Y. Ishikawa, J.Jett, M. Sanchez-Cespedes, J.-P. Sculier, T. Takahashi, M. Tsuboi, J. Vansteenkiste, I.I. Wistuba, P.-C. Yang, D. Aberle, C. Brambilla, D. Flieder, W. Franklin, A. Gazdar, M. Gould, P. Hasleton, D. Henderson, B.Johnson, D. Johnson, K. Kerr, K. Kuriyama, J.S. Lee, V.A. Miller, I. Petersen, V. Roggli, R. Rosell, N. Saijo, E. Thunnissen, M. Tsao, and D. Yankelewitz: International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma; J. Thorac. Oncol. 6 (2011) 244-285.]Search in Google Scholar
[12. Thun, M.J., C.A. Lally, J.T. Flannery, E.E. Calle, W.D. Flanders, and C.W. Heath, Jr: Cigarette Smoking and Changes in the Histopathology of Lung Cancer; J. Natl. Cancer Inst. 89 (1997) 1580-1586.]Search in Google Scholar
[13. Burns, D.M., C.M. Anderson, and N. Gray: Do Changes in Cigarette Design Influence the Rise in Adenocarcinoma of the Lung?; Cancer Causes Control 22 (2011) 13-22.]Search in Google Scholar
[14. Brooks, D.R., J.H.M. Austin, R.T. Heelan, M.S. Ginsberg, V. Shin, S.H. Olson, J.E. Muscat, and S.D. Stellman: Influence of Type of Cigarette on Peripheral versus Central Lung Cancer; Cancer Epidemiol. Biomarkers Prev. 14 (2005) 576-581.]Search in Google Scholar
[15. Chen, F., P. Cole, and W.F. Bina: Time Trend and Geographic Patterns of Lung Adenocarcinoma in the United States, 1973-2002; Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2724-2729.]Search in Google Scholar
[16. Fry, J.S., P.N. Lee, B.A. Forey, and K.J. Coombs: Is The Shape of the Decline in Risk Following Quitting Smoking Similar for Squamous Cell Carcinoma and Adenocarcinoma of the Lung? A Quantitative Review Using The Negative Exponential Model; Regul. Toxicol. Pharmacol. 72 (2015) 49-57.]Search in Google Scholar
[17. Simonato, L., A. Agudo, W. Ahrens, E. Benhamou, S. Benhamou, P. Boffetta, P. Brennan, S.C. Darby, F. Forastiere, C. Fortes, V. Gaborieau, M. Gerken, C.A. Gonzales, K.-H. Jöckel, M. Kreuzer, F. Merletti, F. Nyberg, G. Pershagen, H. Pohlabeln, F. Rösch, E. Whitley, H.-E. Wichmann, and P. Zambon: Lung Cancer and Cigarette Smoking in Europe: An Update of Risk Estimates and an Assessment of Inter-Country Heterogeneity; Int. J. Cancer 91 (2001) 876-887.]Search in Google Scholar
[18. Vogelstein, B. and K.W. Kinzler: Cancer Genes and the Pathways they Control; Nat. Med. 10 (2004) 789-799.]Search in Google Scholar
[19. Vineis, P. and D. Kriebel: Causal Models in Epidemiology: Past Inheritance and Genetic Future; Environ. Health 5 (2006) 21.]Search in Google Scholar
[20. Kerr, K.M.: Clinical Relevance of the New IASLC / ERS / ATS Adenocarcinoma Classification; J. Clin. Pathol. 66 (2013) 832-838. ]Search in Google Scholar
[21. Mundt, K.A., C. Bigelow, and E. van Wijngaarden: Apportionment of Disease in Individuals; J. Clin. Epidemiol. 56 (2003) 290-291; author reply 291.10.1016/S0895-4356(02)00594-2]Search in Google Scholar
[22. Rothman, K.J. and S. Greenland: Causation and Causal Inference in Epidemiology; Am. J. Public Health 95 Suppl 1 (2005) S144-150.10.2105/AJPH.2004.05920416030331]Search in Google Scholar
[23. Greenland, S. and J.M. Robins: Epidemiology, Justice, and the Probability of Causation; Jurimetrics 40 (2000) 321-340.]Search in Google Scholar
[24. Peto, R., S. Darby, H. Deo, P. Silcocks, E. Whitley, and R. Doll: Smoking, Smoking Cessation, and Lung Cancer in the UK since 1950: Combination of National Statistics with Two Case-Control Studies; BMJ 321 (2000) 323-329.]Search in Google Scholar
[25. International Agency for Research on Cancer (IARC): Tobacco Control: Reversal of Risk After Quitting Smoking; IARC Handbooks of Cancer Prevention, Volume 11, IARC Press, Lyon, France, 2007.]Search in Google Scholar
[26. Doll, R., R. Peto, J. Boreham, and I. Sutherland: Mortality in Relation to Smoking: 50 Years’ Observations on Male British Doctors; BMJ 328 (2004) 1519.]Search in Google Scholar
[27. Khuder, S.A. and A.B. Mutgi: Effect of Smoking Cessation on Major Histologic Types of Lung Cancer; Chest 120 (2001) 1577-1583.]Search in Google Scholar
[28. Speizer, F.E., G.A. Colditz, D.J. Hunter, B. Rosner, and C. Hennekens: Prospective Study of Smoking, Antioxidant Intake, and Lung Cancer in Middle-Aged Women (USA); Cancer Causes Control 10 (1999) 475-482.]Search in Google Scholar
[29. Ebbert, J.O., P. Yang, C.M. Vachon, R.A. Vierkant, J.R. Cerhan, A.R. Folsom, and T.A. Sellers: Lung Cancer Risk Reduction After Smoking Cessation: Observations from a Prospective Cohort of Women; J. Clin. Oncol. 21 (2003) 921-926.]Search in Google Scholar
[30. Flanders, W.D., C.A. Lally, B.-P. Zhu, S.J. Henley, and M.J. Thun: Lung Cancer Mortality in Relation to Age, Duration of Smoking, and Daily Cigarette Consumption: Results from Cancer Prevention Study II; Cancer Res. 63 (2003) 6556-6562.]Search in Google Scholar
[31. Lubin, J.H. and N.E. Caporaso: Cigarette Smoking and Lung Cancer: Modeling Total Exposure and Intensity; Cancer Epidemiol. Biomarkers Prev. 15 (2006) 517-523.]Search in Google Scholar
[32. Govindan, R., L. Ding, M. Griffith, J. Subramanian, N.D. Dees, K.L. Kanchi, C.A. Maher, R. Fulton, L. Fulton, J. Wallis, K. Chen, J. Walker, S. McDonald, R. Bose, D. Ornitz, D. Xiong, M. You, D.J. Dooling, M. Watson, E.R. Mardis, and R.K. Wilson: Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers; Cell 150 (2012) 1121-1134. ]Search in Google Scholar
[33. Li, F., Y. Feng, R. Fang, Z. Fang, J. Xia, X. Han, X.-Y. Liu, H. Chen, H. Liu, and H. Ji: Identification of RET Gene Fusion by Exon Array Analyses in "Pan-Negative" Lung Cancer from Never Smokers; Cell Res. 22 (2012) 928-931.]Search in Google Scholar
[34. Sun, S., J.H. Schiller, and A.F. Gazdar: Lung Cancer in Never Smokers--A Different Disease; Nat. Rev. Cancer 7 (2007) 778-790.]Search in Google Scholar
[35. Ou, S.-H.: Lung Cancer in Never-Smokers. Does Smoking History Matter in the Era of Molecular Diagnostics and Targeted Therapy?; J. Clin. Pathol. 66 (2013) 839-846.]Search in Google Scholar
[36. Staaf, J., G. Jönsson, M. Jönsson, A. Karlsson, S. Isaksson, A. Salomonsson, H.M. Pettersson, M. Soller, S.B. Ewers, L. Johansson, P. Jönsson, and M. Planck: Relation between Smoking History and Gene Expression Profiles in Lung Adenocarcinomas; BMC Med Genomics 5 (2012) 22.]Search in Google Scholar
[37. Noguchi, M., A. Morikawa, M. Kawasaki, Y. Matsuno, T. Yamada, S. Hirohashi, H. Kondo, and Y. Shimosato: Small Adenocarcinoma of the Lung. Histologic Characteristics and Prognosis; Cancer 75 (1995) 2844-2852.]Search in Google Scholar
[38. Colby, T., M. Noguchi, and C. Henschke: Adenocarcinoma; in: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart; 3rd ed., edited by W.B. Travis, E. Brambilla, H.K. Müller-Hermlink, and C.C. Harris, International Agency for Research on Cancer, Lyon, France, 2004, pp 35-44.]Search in Google Scholar
[39. Motoi, N., J. Szoke, G.J. Riely, V.E. Seshan, M.G. Kris, V.W. Rusch, W.L. Gerald, and W.D. Travis: Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis; Am. J. Surg. Pathol. 32 (2008) 810-827.]Search in Google Scholar
[40. Nassar, H.: Carcinomas with Micropapillary Morphology: Clinical Significance and Current Concepts; Adv. Anat. Pathol. 11 (2004) 297-303. ]Search in Google Scholar
[41. Rekhtman, N., P.K. Paik, M.E. Arcila, L.J. Tafe, G.R. Oxnard, A.L. Moreira, W.D. Travis, M.F. Zakowski, M.G. Kris, and M. Ladanyi: Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations; Clin. Cancer Res. 18 (2012) 1167-1176.]Search in Google Scholar
[42. Dogan, S., R. Shen, D.C. Ang, M.L. Johnson, S.P. D’Angelo, P.K. Paik, E.B. Brzostowski, G.J. Riely, M.G. Kris, M.F. Zakowski, and M. Ladanyi: Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers; Clin. Cancer Res. 18 (2012) 6169-6177. ]Search in Google Scholar
[43. Girard, N., C.S. Sima, D.M. Jackman, L.V. Sequist, H. Chen, J.C.-H. Yang, H. Ji, B. Waltman, R. Rosell, M. Taron, M.F. Zakowski, M. Ladanyi, G. Riely, and W. Pao: Nomogram to Predict the Presence of EGFR Activating Mutation in Lung Adenocarcinoma; Eur. Respir. J. 39 (2012) 366-372.]Search in Google Scholar
[44. Imielinski, M., A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M.S. Lawrence, P. Stojanov, K. Cibulskis, K. Choi, L. de Waal, T. Sharifnia, A. Brooks, H. Greulich, S.Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansén, C.Ludwig, W. Engel-Riedel, E. Stoelben, J. Wolf, C. Goparju, K. Thompson, W. Winckler, D. Kwiatkowski, B.E. Johnson, P.A. Jänne, V.A. Miller, W. Pao, W.D. Travis, H.I. Pass, S.B. Gabriel, E.S. Lander, R.K. Thomas, L.A. Garraway, G. Getz, and M. Meyerson: Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing; Cell 150 (2012) 1107-1120.]Search in Google Scholar
[45. Kris, M.G., B.E. Johnson, L.D. Berry, D.J. Kwiat Kwiatkowski, A.J. Iafrate, I.I. Wistuba, M. Varella-Garcia, W.A. Franklin, S.L. Aronson, P.-F. Su, Y. Shyr, D.R. Camidge, L.V. Sequist, B.S. Glisson, F.R. Khuri, E.B. Garon, W. Pao, C. Rudin, J. Schiller, E.B. Haura, M. Socinski, K. Shirai, H. Chen, G. Giaccone, M. Ladanyi, K. Kugler, J.D. Minna, and P.A. Bunn: Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs; JAMA 311 (2014) 1998-2006.]Search in Google Scholar
[46. Lindeman, N.I., P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, G. Giaccone, R.B. Jenkins, D.J. Kwiatkowski, J.-S. Saldivar, J. Squire, E. Thunnissen, and M. Ladanyi: Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology; Arch. Pathol. Lab. Med. 137 (2013) 828-860.]Search in Google Scholar
[47. Shigematsu, H., L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I.I. Wistuba, K.M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J.A. Roth, J. Herz, J.D. Minna, and A.F. Gazdar: Clinical and Biological Features Associated with Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers; J. Natl. Cancer Inst. 97 (2005) 339-346.]Search in Google Scholar
[48. Kim, H.R., J.R. Ahn, J.G. Lee, D.H. Bang, S.-J. Ha, Y.K. Hong, S.M. Kim, K.C. Nam, S.Y. Rha, R.A. Soo, G.J. Riely, J.H. Kim, and B.C. Cho: The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma; Yonsei Med. J. 54 (2013) 865-874.]Search in Google Scholar
[49. Kim, H.R., H.S. Shim, J.-H. Chung, Y.J. Lee, Y.K. Hong, S.Y. Rha, S.H. Kim, S.-J. Ha, S.K. Kim, K.Y. Chung, R. Soo, J.H. Kim, and B.C. Cho: Distinct Clinical Features and Outcomes in Never-Smokers with Nonsmall Cell Lung Lancer who Harbor EGFR or KRAS Mutations or ALK rearrangement; Cancer 118 (2012) 729-739.]Search in Google Scholar
[50. Riely, G.J., M.G. Kris, D. Rosenbaum, J. Marks, A. Li, D.A. Chitale, K. Nafa, E.R. Riedel, M. Hsu, W. Pao, V.A. Miller, and M. Ladanyi: Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma; Clin. Cancer Res. 14 (2008) 5731-5734.]Search in Google Scholar
[51. Riely, G.J., J. Marks, and W. Pao: KRAS Mutations in Non-Small Cell Lung Cancer; Proc. Am. Thorac. Soc. 6 (2009) 201-205.]Search in Google Scholar
[52. Smits, A.J.J., J.A. Kummer, J.W.J. Hinrichs, G.J.M. Herder, K.C. Scheidel-Jacobse, N.M. Jiwa, T.E.G. Ruijter, P.T.G.A. Nooijen, M.G. Looijen-Salamon, M.J.L. Ligtenberg, F.B. Thunnissen, D.A.M. Heideman, R.A. de Weger, and A. Vink: EGFR and KRAS Mutations in Lung Carcinomas in the Dutch Population: Increased EGFR Mutation Frequency in Malignant Pleural Effusion of Lung Adenocarcinoma; Cell. Oncol. 35 (2012) 189-196.]Search in Google Scholar
[53. Cardarella, S., A. Ogino, M. Nishino, M. Butaney, J. Shen, C. Lydon, B.Y. Yeap, L.M. Sholl, B.E. Johnson, and P.A. Jänne: Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non- Small Cell Lung Cancer; Clin. Cancer Res. 19 (2013) 4532-4540.]Search in Google Scholar
[54. Marchetti, A., L. Felicioni, S. Malatesta, M. Grazia Sciarrotta, L. Guetti, A. Chella, P. Viola, C. Pullara, F. Mucilli, and F. Buttitta: Clinical Features and Outcome of Patients with Non-Small-Cell Lung Cancer Harboring BRAF Mutations; J. Clin. Oncol. 29 (2011) 3574-3579. ]Search in Google Scholar
[55. Paik, P.K., M.E. Arcila, M. Fara, C.S. Sima, V.A. Miller, M.G. Kris, M. Ladanyi, and G.J. Riely: Clinical Characteristics of Patients with Lung Adenocarcinomas Harboring BRAF Mutations; J. Clin. Oncol. 29 (2011) 2046-2051.]Search in Google Scholar
[56. Sasaki, H., M. Shitara, K. Yokota, K. Okuda, Y. Hikosaka, S. Moriyama, M. Yano, and Y. Fujii: Braf and erbB2 Mutations Correlate with Smoking Status in Lung Cancer Patients; Exp. Ther. Med. 3 (2012) 771-775.]Search in Google Scholar
[57. Arcila, M.E., J.E. Chaft, K. Nafa, S. Roy-Chowdhuri, C. Lau, M. Zaidinski, P.K. Paik, M.F. Zakowski, M.G. Kris, and M. Ladanyi: Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas; Clin. Cancer Res. 18 (2012) 4910-4918.]Search in Google Scholar
[58. Mazières, J., S. Peters, B. Lepage, A.B. Cortot, F. Barlesi, M. Beau-Faller, B. Besse, H. Blons, A. Mansuet-Lupo, T. Urban, D. Moro-Sibilot, E. Dansin, C. Chouaid, M. Wislez, J. Diebold, E. Felip, I. Rouquette, J.D. Milia, and O. Gautschi: Lung Cancer that Harbors a HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives; J. Clin. Oncol. 31 (2013) 1997-2003.]Search in Google Scholar
[59. Shigematsu, H., T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, I.I. Wistuba, K.M. Fong, S. Toyooka, N. Shimizu, T. Fujisawa, J.D. Minna, and A.F. Gazdar: Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas; Cancer Res. 65 (2005) 1642-1646.]Search in Google Scholar
[60. Sonobe, M., T. Manabe, H. Wada, and F. Tanaka: Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain; J. Mol. Diagn. 8 (2006) 351-356.]Search in Google Scholar
[61. Bergethon, K., A.T. Shaw, S.-H.I. Ou, R. Katayama, C.M. Lovly, N.T. McDonald, P.P. Massion, C. Siwak- Tapp, A. Gonzalez, R. Fang, E.J. Mark, J.M. Batten, H. Chen, K.D. Wilner, E.L. Kwak, J.W. Clark, D.P. Carbone, H. Ji, J.A. Engelman, M. Mino-Kenudson, W. Pao, and A.J. Iafrate: ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers; J. Clin. Oncol. 30 (2012) 863-870.]Search in Google Scholar
[62. Cha, Y.J., J.S. Lee, H.R. Kim, S.M. Lim, B.C. Cho, C.Y. Lee, and H.S. Shim: Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements; PLoS ONE 9 (2014) e103333.]Search in Google Scholar
[63. Shan, L., F. Lian, L. Guo, T. Qiu, Y. Ling, J. Ying, and D. Lin: Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR; PLoS ONE 10 (2015) e0120422.]Search in Google Scholar
[64. Lee, S.E., B. Lee, M. Hong, J.-Y. Song, K. Jung, M.E. Lira, M. Mao, J. Han, J. Kim, and Y.L. Choi: Comprehensive Analysis of RET and ROS1 Rearrangement in Lung Adenocarcinoma; Mod. Pathol. 28 (2015) 468-479. ]Search in Google Scholar
[65. Yokota, K., H. Sasaki, K. Okuda, S. Shimizu, M. Shitara, Y. Hikosaka, S. Moriyama, M. Yano, and Y. Fujii: KIF5B/RET Fusion Gene in Surgically-Treated Adenocarcinoma of the Lung; Oncol. Rep. 28 (2012) 1187-1192.]Search in Google Scholar
[66. Kim, H. and J.-H. Chung: Overview of Clinicopathologic Features of ALK-Rearranged Lung Adenocarcinoma and Current Diagnostic Testing for ALK Rearrangement; Transl. Lung Cancer Res. 4 (2015) 149-155.]Search in Google Scholar
[67. Koh, Y., D.-W. Kim, T.M. Kim, S.-H. Lee, Y.K. Jeon, D.H. Chung, Y.-W. Kim, D.S. Heo, W.-H. Kim, and Y.-J. Bang: Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase- Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for these Tumors; J. Thorac. Oncol. 6 (2011) 905-912.]Search in Google Scholar
[68. Li, Y., Y. Li, T. Yang, S. Wei, J. Wang, M. Wang, Y. Wang, Q. Zhou, H. Liu, and J. Chen: Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer; PLoS ONE 8 (2013) e52093.]Search in Google Scholar
[69. Oxnard, G.R., K.-S. Nguyen, and D.B. Costa: Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History; J. Natl. Cancer Inst. 106 (2014) djt361.10.1093/jnci/djt36124317178]Search in Google Scholar
[70. Wang, Y., S. Wang, S. Xu, J. Qu, and B. Liu: Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis; PLoS ONE 9 (2014) e110617.]Search in Google Scholar
[71. Lynch, T.J., D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small- Cell Lung Cancer to Gefitinib; N. Engl. J. Med. 350 (2004) 2129-2139.]Search in Google Scholar
[72. Paez, J.G., P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson: EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy; Science 304 (2004) 1497-1500.]Search in Google Scholar
[73. Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus: EGF Receptor Gene Mutations are Common in Lung Cancers from "Never Smokers" and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib; Proc. Natl. Acad. Sci. U S A 101 (2004) 13306-13311.]Search in Google Scholar
[74. D’Angelo, S.P., M.C. Pietanza, M.L. Johnson, G.J. Riely, V.A. Miller, C.S. Sima, M.F. Zakowski, V.W. Rusch, M. Ladanyi, and M.G. Kris: Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens from Men and Cigarette Smokers with Lung Adenocarcinomas; Clin. Oncol. 29 (2011) 2066-2070.]Search in Google Scholar
[75. Thu, K.L., E.A. Vucic, R. Chari, W. Zhang, W.W. Lockwood, J.C. English, R. Fu, P. Wang, Z. Feng, C.E. MacAulay, .F. Gazdar, S. Lam, and W.L. Lam: Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability; PLoS ONE 7 (2012) e33003.]Search in Google Scholar
[76. Leary, A.F., D. Gonsalez de Castro, A.G. Nicholson, S. Ashley, A. Wotherspoon, M.E.R. O’Brien, and S. Popat: Establishing an EGFR Mutation Screening Service for Non-Small Cell Lung Cancer - Sample Quality Criteria and Candidate Histological Predictors; Eur. J. Cancer 48 (2012) 61-67.]Search in Google Scholar
[77. Li, H., Y. Pan, Y. Li, C. Li, R. Wang, H. Hu, Y. Zhang, T. Ye, L. Wang, L. Shen, Y. Sun, and H. Chen: Frequency of Well-Identified Oncogenic Driver Mutations in Lung Adenocarcinoma of Smokers Varies with Histological Subtypes and Graduated Smoking Dose; Lung Cancer 79 (2013) 8-13.]Search in Google Scholar
[78. Jänne, P.A., A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, C. Barrios, F.A. Franke, L. Grinsted, V. Zazulina, P. Smith, I. Smith, and L. Crinò: Selumetinib plus Docetaxel for KRAS-Mutant Advanced Non- Small-Cell Lung Cancer: A Randomised, Multicentre, Placebo-Controlled, Phase 2 Study; Lancet Oncol. 14 (2013) 38-47.]Search in Google Scholar
[79. Tsuta, K., M. Kawago, E. Inoue, A. Yoshida, F. Takahashi, H. Sakurai, S.-I. Watanabe, M. Takeuchi, K. Furuta, H. Asamura, and H. Tsuda: The Utility of the Proposed IASLC/ATS/ERS Lung Adenocarcinoma Subtypes for Disease Prognosis and Correlation of Driver Gene Alterations; Lung Cancer 81 (2013) 371-376.]Search in Google Scholar
[80. Maeda, R., G. Ishii, J. Yoshida, T. Hishida, M. Nishimura, and K. Nagai: Influence of Cigarette Smoking on Histological Subtypes of Stage I Lung Adenocarcinoma; J. Thorac. Oncol. 6 (2011) 743-750.]Search in Google Scholar
[81. Sakao, Y., H. Miyamoto, S. Oh, N. Takahashi, T.Inagaki, Y. Miyasaka, T. Akaboshi, and M. Sakuraba: The Impact of Cigarette Smoking on Prognosis in Small Adenocarcinomas of the Lung: The Association between Histologic Subtype and Smoking Status; J.Thorac. Oncol. 3 (2008) 958-962.]Search in Google Scholar
[82. Hu, H., Y. Pan, Y. Li, L. Wang, R. Wang, Y. Zhang, H. Li, T. Ye, Y. Zhang, X. Luo, L. Shao, Z. Sun, D. Cai, J. Xu, Q. Lu, Y. Deng, L. Shen, H. Ji, Y. Sun, and H. Chen: Oncogenic Mutations Are Associated with Histological Subtypes but do Not Have an Independent Prognostic Value in Lung Adenocarcinoma; Onco. Targets Ther. 7 (2014) 1423-1437.]Search in Google Scholar
[83. Miyoshi, T., Y. Satoh, S. Okumura, K. Nakagawa, T. Shirakusa, E. Tsuchiya, and Y. Ishikawa: Early-Stage Lung Adenocarcinomas with a Micropapillary Pattern, a Distinct Pathologic Marker for a Significantly Poor Prognosis; Am. J. Surg. Pathol. 27 (2003) 101-109.]Search in Google Scholar
[84. Villa, C., P.T. Cagle, M. Johnson, J.D. Patel, A.V. Yeldandi, R. Raj, M.M. DeCamp, and K. Raparia: Correlation of EGFR Mutation Status with Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society; Arch. Pathol. Lab. Med. 138 (2014) 1353-1357.]Search in Google Scholar
[85. An, S.-J., Z.-H. Chen, J. Su, X.-C. Zhang, W.-Z. Zhong, J.-J. Yang, Q. Zhou, X.-N. Yang, L. Huang, J.- L. Guan, Q. Nie, H.-H. Yan, T.S. Mok, and Y.-L. Wu: Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status; PLoS ONE 7 (2012) e40109.]Search in Google Scholar
[86. Huang, S.-F., H.-P. Liu, L.-H. Li, Y.-C. Ku, Y.-N. Fu, H.-Y. Tsai, Y.-T. Chen, Y.-F. Lin, W.-C. Chang, H.-P. Kuo, Y.-C. Wu, Y.-R. Chen, and S.-F. Tsai: High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non-Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan; Clin. Cancer Res. 10 (2004) 8195-8203.]Search in Google Scholar
[87. Yano, T., A. Haro, Y. Shikada, R. Maruyama, and Y. Maehara: Non-Small Cell Lung Cancer in Never Smokers as a Representative ’Non-Smoking-Associated Lung Cancer’: Epidemiology and Clinical Features; Int. J. Clin. Oncol. 16 (2011) 287-293.]Search in Google Scholar
[88. Paik, P.K., M.L. Johnson, S.P. D’Angelo, C.S. Sima, D. Ang, S. Dogan, V.A. Miller, M. Ladanyi, M.G. Kris, and G.J. Riely: Driver Mutations Determine Survival in Smokers and Never-Smokers with Stage IIIB/IV Lung Adenocarcinomas; Cancer 118 (2012) 5840-5847.]Search in Google Scholar
[89. Karlsson, A., M. Ringnér, M. Lauss, J. Botling, P. Micke, M. Planck, and J. Staaf: Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History; Clin. Cancer Res. 20 (2014) 4912-4924.]Search in Google Scholar
[90. Krishnan, V.G., P.J. Ebert, J.C. Ting, E. Lim, S.-S. Wong, A.S.M. Teo, Y.G. Yue, H.-H. Chua, X. Ma, G.S.L. Loh, Y. Lin, J.H.J. Tan, K. Yu, S. Zhang, C.Reinhard, D.S.W. Tan, B.A. Peters, S.E. Lincoln, D.G.Ballinger, J.M. Laramie, G.B. Nilsen, T.D. Barber, P.Tan, A.M. Hillmer, and P.C. Ng: Whole-Genome Sequencing of Asian Lung Cancers: Second-Hand Smoke Unlikely to be Responsible for Higher Incidence of Lung Cancer Among Asian Never-Smokers; Cancer Res. 74 (2014) 6071-6081.]Search in Google Scholar
[91. Tomashefski, J.F., Jr, P.T. Cagle, C.F. Farver, and A.E. Fraire: Dail and Hammar’s Pulmonary Pathology, Vol. II, Neoplastic Lung Disease, 3rd ed.; Springer, New York, NY, 2010. ]Search in Google Scholar
[92. Sato, S., N. Motoi, M. Hiramatsu, E. Miyauchi, H.]Search in Google Scholar
[Ono, Y. Saito, H. Nagano, H. Ninomiya, K. Inamura, H. Uehara, M. Mun, Y. Sakao, S. Okumura, M. Tsuchida, and Y. Ishikawa: Pulmonary Adenocarcinoma in Situ: Analyses of a Large Series with Reference to Smoking, Driver Mutations, and Receptor Tyrosine Kinase Pathway Activation; Am. J. Surg. Pathol. 39 (2015) 912-921. ]Search in Google Scholar
